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ABSTRACT 
PYRUVATE DEHYDROGENASE ACTIVITY IN RESPONSE TO SKELETAL 
MUSCLE CONTRACTION AT TWO STIMULATION FREQUENCIES IN 
PYRUVATE DEHYDROGENASE KINASE 2 KNOCKOUT MICE 
Emily Dunford Supervisor: 
Brock University 2009 Dr. Sandra J. Peters 
Pyruvate dehydrogenase (PDH) plays an important role in regulating carbohydrate 
oxidation in skeletal muscle. PD H is deactivated by a set of PD H kinases (PD K 1-4) with 
PDK2 and 4 being the predominant isoforms in skeletal muscle. PDK2 is highly sensitive 
to pyruvate inhibition, and is the most abundant isoform, while PDKI and 4 protein 
content are normally lower. This study examined the PDK isoform content and PDHa 
activation in muscle at rest and 10 and 40 Hz stimulation from PDK2 knockout 
(PDK2KO) mice to delineate the role of PDK2 in activating the PDH complex during 
low and moderate intensity muscle contraction. PDHa activity was lower in PDK2KO 
mice during contraction while total PDK actitvity was -4 fold lower. PDK4 protein was 
not different, however PDKI partially compensated for the lack of PDK2 and was -56% 
higher than WT. PDKI is a very potent inhibitor of the PDH complex due to its 
phosphorylation site specificity and allosteric regulation. These results suggest that the 
site specificity and allosteric regulatory properties of the individual PDK isoforms are 
more important than total PDK activity in determining transformation of the complex and 
PDHa activity during acute muscle contraction. 
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CHAPTERl 
INTRODUCTION 
The utilization of carbohydrates and fat by skeletal muscle for energy is a very 
important and well documented process. The pyruvate dehydrogenase (PDH) complex is 
a major player in the oxidation of carbohydrates, specifically in the rate-limiting 
conversion of pyruvate to acetyl-CoA. This complex is extremely important as it links 
glycolysis to the tricarboxylic cycle (TCA cycle) by regulating the entrance of 
carbohydrate-derived acetyl units into the TCA cycle (Harris et al. 2002). 
The PDH complex is regulated by two enzyme families, the PDH kinases (PDK1-
4) and the PDH phosphatases (PDPI and 2). The two families work in opposition to one 
another as the main role of PDK is to phosphorylate and deactivate the PDH complex, 
while PDP works to dephosphorylate and reactivate the PDH complex. PDK2 and 4 are 
the predominate isoforms in skeletal muscle, and are therefore believed to mediate the 
majority of PDH complex deactivation in this tissue. Additionally, the individual 
isoforms respond differently to intramitochondrial effector concentrations, adding 
another level of regulation (Harris et al. 2002) (see appendix for more individual kinase 
information). Therefore, the population of the different PDKs at any given time will help 
determine how the complex behaves with any acute intervention such as during dietary 
perturbations (Wu et al. 1998, Wu et al. 1999), exercise (Watt et al. 2002, Watt et al. 
2004) or exercise training (LeBlanc et al. 2004). 
The PDK2 isoform is the most ubiquitous and abundantly expressed isoform in all 
tissues, with especially high concentrations in the liver, heart, kidney and skeletal muscle 
(Sugden and Holness, 2003). PDK2 is highly sensitive to pyruvate inhibition (Bowker-
Kinley et ai., 1998), and is known to increase in skeletal muscle with exercise training 
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(LeBlanc et ai., 2004), but is generally relatively unchanged with dietary perturbations 
such as starvation and high fat diets (Holness et al. 2000, Peters et al. 2001, Jeoung et aI., 
2006). This thesis will examine the role that PDK2 would normally play determining the 
activation of the PDH complex during low and moderate intensity muscle contraction 
through the examination of genetically modified mice that are missing (or "knocked out") 
the PDK2 gene. Using a knockout model has its limitations, because it has been 
genetically manipulated and might not reflect a physiologically accurate environment. In 
many cases, using this severe genetic approach can induce adaptations to compensate. 
Although this should be taken into consideration, using a knockout model allows 
isolation of the removed gene, and permits the analysis of the effect of its deletion. 
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CHAPTER 2 
LITERATURE REVIEW 
PDHComplex 
a) Role in Metabolism 
PDH plays a pivotal role in the regulation of glucose homeostasis by catalyzing 
the oxidative decarboxylation of pyruvate to acetyl-CoA. This reaction links glycolysis to 
the TCA cycle, as PDH controls carbohydrate oxidation by regulating the entrance of 
carbohydrate derived acetyl units into the TCA cycle. Consequentially, adequate flux 
through PDH is important for tissues with a high ATP requirement, including exercising 
muscle. Suppression of PDH activity is crucial for conservation of carbohydrates (and to 
facilitate fatty acid oxidation) when these are in short supply (Sugden and Holness, 
2003). 
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Figure 1. The regulation of PDHa activity through reversible phosphorylation. 
Relative degree of phosphorylation of the El-alpha subunit is determined by kinases 
(PDKI-4) and phosphatases (PDPI and 2). Regulators of phosphatases and kinases are 
highlighted. EI is shown in blue, E2 is shown in green and E3 is shown in yellow. (Maj 
et al. 2006) 
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b) Structure of the Complex 
The PDH complex is built around a 60 subunit inner core of tightly associated 
dihydrolipoamide acetyltransferase subunits (E2). Each E2 subunit has an inner region 
that forms the core and an outer region that extends from the core which binds the El 
enzyme. The El enzyme is responsible for the irreversible decarboxylation of pyruvate 
and each outer region consists of three self-folding domains connected in series. 
Dihydrolipoamide dehydrogenase (E3) is responsible for oxidation of E2 and the 
production of NADH in an FAD-linked reaction. E3-binding protein is not catalytic and 
only plays a structural role in the binding of E3 to the complex [Fig. 1]. It has been 
proposed that 48 subunits of E2 and twelve subunits of E3BP form the central core of the 
PDH complex (Harris et al. 2002, Patel and Korotchkina, 2006). The PDH complex also 
contains two families of regulatory enzymes, the PDH kinases (PDKs) of which there are 
four isoforms (PDKI-4), and the PDH phosphatases (PDPs) of which there are two 
isoforms (PDPI and PDP2). Both enzymes catalyze a phosphorylation-dephosphorylation 
cycle which involves specific phosphorylation sites on the El-a subunit (Wieland, 1983). 
The phosphorylation of the El-a subunit renders the PDH complex completely inactive 
(Linn et al. 1969) and occurs at three specific serine residues (Yeaman et al. 1978). The 
three serine residues are serine-264 (designated site 1) serine-271 (designated site 2) and 
serine-203 (designated site 3) and have been designated as a result of the rate of 
phosphorylation (Yeaman et al. 1978). Through study of phosphorylation rates of the rat 
heart, it was determined that phosphorylation of site 1 is the most rapid while 
phosphorylation of site 3 is the least rapid (Sale and Randle, 1981). It was also 
determined that site 1 is the site of major inactivation in bovine kidney and is responsible 
for 60-70% of occurring inactivation, while sites 2 and 3 only add to the inactivation 
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(Yeaman et al. 1978). As such, phosphorylation of only one site renders this component 
inactive (Patel and Korotchkina, 2006), specifically, phosphorylation of site 1 is 
correlated with major inactivation, while increased occupancy of sites 2 and 3 renders the 
complex less sensitive to activation by PDP (Korotchkina and Patel, 1995, Korotchkina et 
al. 1995). The specific regulation of these enzymes will be discussed in greater detail 
later. 
c) Regulation of the complex 
i) Covalent and Allosteric regulation 
Physiologically, the complex is rarely completely active or inactive and the 
proportion of collective complex activity is determined by the relative activities of the 
PDH kinases and the opposing PDH phosphatases (Harris et al. 2002). 
The PDKs are regulated allosterically by the mitochondrial concentrations of 
pyruvate, ADP and Pi, and NADHlNAD+ and acetyl-CoAiCoA ratios [Fig. 2]. Pyruvate 
is of particular importance as its concentration fluctuates markedly during different 
metabolic states and exercise conditions (Harris et al. 2002). High pyruvate levels inhibit 
PDK activity, upregulating the complex, while a high energy state, high levels of ATP, 
NADH, acetyl-CoA, increases PDK activity to down regulate the complex. NADH and 
acetyl-CoA, products of the PDH reaction, remain bound to the complex when they 
accumulate, which in turn affects the amount of PDK bound to E2. Binding of the PDK 
to an E2 domain results in higher kinase activity and an increase in PDH down-regulation 
(Patel and Korotchkina, 2006). 
PDP1 requires Mg2+ but is allosterically stimulated by Ca2+. Conditions that cause 
an increase in Ca2+ concentration, like muscle contraction, will stimulate the activity of 
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PDPl and therefore the activity of the PDH complex. The second PDP isoforrn (PDP2) is 
not activated by Ca2+ and needs higher Mg2+ concentrations for activation. Therefore, it is 
presumably sensitive to nutritional perturbations, through changes in insulin 
concentration (Huang et al. 2003). 
/ ~/ 
Tell. 
CVCI .. E 
Figure 2. Regulation of the PDH complex. PDK - Pyruvate dehydrogenase kinase; PDP 
- Pyruvate dehydrogenase phosphatase; PDC- Pyruvate Dehydrogenase Complex 
(Sugden & Holness, 2003). 
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PDK 2 and 4 
a) Discovery and Biochemical Properties 
Early studies had found that high fat feeding over 19-23 days created a marked 
decline in PDHa activity without a change in total PDH activity (Fuller and Randle, 
1984). The mechanism behind this response was studied earlier by Hutson and Randle 
(1978), who focused on the mitochondrial effectors for an explanation. The authors found 
that there was an increase in PDK activity in rat heart mitochondria from diabetic and 
48h starved rats. The increase seen in PDK activity persisted even after the mitochondrial 
effectors had been washed away during mitochondrial extractions. Demonstrating that the 
response observed was unrelated to acute changes in mitochondrial effectors and was 
therefore termed a "stable increase" in PDK activity (Hutson and Randle, 1978). 
Additional work to determine the reason for the stable increase in PDK activity 
centered around free PDK and/or an activator of the kinase termed the "kinase activator 
protein" (KAP) (Kerbey and Randle, 1982). KAP was found to increase during diabetes 
and starvation and the increase was reversed by re-feeding of the starved rats. However, 
both Mistry et al. (1991) and Jones and Yeaman (1991) simultaneously demonstrated that 
the KAP found in liver mitochondria was actually unbound kinase, therefore eliminating 
the concept of an activator protein for PDK. 
More recent work discovered that there were four PDK isoforms (Priestman et al. 
1994, Gudi et al. 1996, Rowles et al. 1996, Bowker-Kinley et al. 1998). The first 
successful attempt of purification of PDK reported that the PDK enzyme existed as two 
subunits of 48 and 45 kDa, designated as a- and ~-subunits. Kinase activity was believed 
to reside solely in the a-subunit while the function of the ~-subunit was unknown. It was 
suggested that the ~-subunit might be involved in regulation. Priestman et al. (1994) first 
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suggested that the a-subunit was not the only active kinase, by demonstrating that 
antibodies directed against this subunit did not detect enough PDK protein to account for 
the full increase in PDK activity observed during starvation. Once it was determined that 
both the a and ~ proteins were catalytically active, it was clear that they were not subunits 
at all, but two different isoforms with different specific activity that were renamed PDK1 
and 2 respectively (Popov et al. 1994, Priestman et al. 1994). Specifically, the primary 
structure of PDK1 was identified as a 48-kDa kinase while PDK2 was a 45-kDa kinase. 
Gudi et al. (1996) uncovered the third PDK isoform in humans, which was called 
PDK3. Previously, most of the studies of the regulation of PDH activity had been 
performed on purified preparations of the PDH complex or the mitochondria prepared 
from different tissues with unspecified amounts of PDK which meant that the question of 
individual contributions of PDK isoforms had never really been addressed. These authors 
then compared the three isoforms using an in vitro ATP-dependent inactivation assay, 
which measured the rate of inactivation of PDH activity due to phosphorylation (Gudi et 
al. 1996). PDK3, another 45-kDa kinase, was found to be the most active isoform. The 
specific activity of PDK1 was about 30-50% lower than PDK3 while PDK2 had the 
lowest basal activity of all three enzymes (Gudi et al. 1996). However, these results could 
be misleading as the kinase activity rate in vivo depends upon the intramitochondrial 
concentrations of products and substrates of the dehydrogenase reaction. 
The fourth PDK isoform was identified by Rowles et al. (1996). The authors studied 
Pima Indians, who have the highest known prevalence of type 2 diabetes, to determine 
the genetic sequence of the newly discovered PDK4 isoform. It was found that the PDK4 
gene was associated with the gene defect which is prominent in Pima Indians and 
correlated strongly with the prevalence of type 2 diabetes. 
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Bowker-Kinley et al. (1998) provided evidence that the isoforms ofPDK were 
responsible for tissue-specific regulation of PDH complex activity. The authors found 
that of the four isoforms studied, only PDK2 was ubiquitously and abundantly expressed, 
suggesting that PDK2 is the major isoform responsible for metabolic control over PDH. 
PDK4 was expressed in skeletal muscle and heart and when compared to PDK2 was 
shown to have a higher specific activity but a lower sensitivity to dichloroacetate (the 
synthetic analogue of pyruvate). PDK3 was the most unique because of its high specific 
activity and unique allosteric regulation. PDK3 showed little response to NADH, while 
the simultaneous presence of NADH and acetyl-CoA resulted in 50% of its inactivation 
(Bowker-Kinley et al. 1998). Its activity is the highest out of the four isoforms, and its 
expression is extremely low in most rat tissues except the testes. Finally, the role of 
PDK1 is the most unknown, as its tissue distribution is limited to the heart muscle, and 
oxidative skeletal muscle (Bowker-Kinley et al. 1998, Peters et al. 2001). PDK1 has a 
higher specific activity than both PDK2 and PDK4 and is even more sensitive to 
inhibition by dichloroacetate and ADP. The primary structure of the four isoforms is 
similar, with 66-74% identity, while between PDK1 and PDK2 there is 70% identity. The 
conclusions drawn by these authors centre around the idea that PDK1 and PDK2 
isoforms are specialized for short-term/metabolic control of PDH activity, while PDK4 is 
more involved in the regulation of adaptive responses to nutritional changes such as 
starvation (Bowker-Kinley et al. 1998; Sugden et al. 2003). 
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b) PDK2 and PDK4 in Starvation, Diabetes and Following a High Fat Diet 
The mechanisms of adaptive regulation of the PDH complex are not well understood 
and usually occur as the result of changes in enzyme activity and/or protein content. The 
most studied conditions surrounding the adaptive regulation of the PDH complex are 
food-restriction, high fat-diets and chemically-induced diabetes. These conditions involve 
a decrease in carbohydrate utilization and an increased reliance on free fatty acid (FFA) 
metabolism as well as increased beta-oxidation. An increase in PDK activity will cause a 
functional shift in PDH from the active form to the inactive form through enhanced 
phosphorylation (Harris et al. 2002; Sugden et al. 200; Peters et al. 2001; Wu et al. 1999). 
In more acute situations there is an increase in beta-oxidation and both the NADHJNAD+ 
and acetyl-CoA/CoA ratios can regulate the complex. 
One of the first studies to provide an explanation for this mechanism tested the 
hypothesis that starvation and diabetes may increase the amount of one or more of the 
PDK isoforms in the rat heart (Wu et al. 1998). After 48 h starvation, a 2-3 fold increase 
in PDK activity was found, with a greater than 3-fold increase in the amount of PDK4 
protein, while PDK2 was unaltered. Streptozotocin treatment was used to induce a type 1 
diabetes-like state by destroying the insulin-producing beta cells of the pancreas. A stable 
increase in PDK activity was also seen after this treatment, with a significant increase in 
PDK4 protein content and no change in PDK2 protein content. The authors then tested 
the diabetic rats to see if the effects on PDK activity and PDK4 expression could be 
reversed by insulin. The treatment of the diabetic rats with insulin decreased the level of 
PDK4 protein almost to the level seen in the control rats. This demonstrated that a large 
increase in the amount of rat PDK4 protein correlated with the stable increase in PDK 
activity normally seen in starved and diabetic rats. The magnitude of the PDK isoform 
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shift induced by starvation and diabetes appears to be almost entirely accounted for by 
PDK4 protein expression (Wu et al. 1998). 
These same investigators examined rat skeletal muscle to see if there would be a 
similar increase in the PDK4 isoform (Wu et al. 1999). The authors hypothesized that the 
increase in long-chain fatty acids caused by starvation and chemically induced diabetes 
would increase PDK4 expression through activation of the peroxisome proliferator-
activated receptor-a (PPAR-a) which is a transcription factor that regulates the 
expression of certain genes. PDK activities from mitochondria isolated from skeletal 
muscle (mixed gastrocnemius) were shown to increase nearly three-fold following the 
48-h starvation and nearly four-fold with streptozotocin-induced diabetes. It was found 
that PDK2 and PDK4 were expressed in significant amounts in rat skeletal muscle with 
these perturbations. Feeding the rats the known agonist for PPAR-a (WY-14, 643) 
mimicked the effect of starvation and diabetes on PDK4 expression causing 3-5 fold 
increases in this isoform in the gastrocnemius muscle. This confirmed that PP AR -a could 
be stimulated by fatty acids and was at least one mechanism to increase expression of 
PDK4 (Wu et al. 1999). 
Skeletal muscle is not homogenous, there are three types of fibres which are 
organized based on their contractile capabilities: type I (slow-twitch oxidative), type lIA 
(fast-twitch oxidative glycolytic), and type IIB (fast-twitch glycolytic) with the balance 
made of transition fibers (type IIXlIID) (De1p and Duan, 1996). In the fed state, oxidative 
slow-twitch muscles have higher glucose utilization rates than fast-twitch muscle fibres, 
which tend to be recruited during exercise (Putman et al. 1993). 
Peters et al. (2001) examined PDK activity and PDK isoform protein changes in rat 
soleus (84% type I, 7% type IIA, 0% type lIB) red gastrocnemius (30-51 % type I, 35-
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62% type lIA, 1-8% type IIB) and white gastrocnemius (0% type 1, 0% type IIA, 92% 
type IIB) muscles over a 24 h fasting period (Peters et al. 2001). Rat skeletal muscle only 
has measureable quantities of the PDK 1, 2 and 4 isoforms and this study was the first to 
examine the PDK activity changes in all three PDK isoforms. The authors found that the 
fast twitch-glycolytic fibres differed from the oxidative fibers in PDK activity. There was 
an increase in PDK activity in all muscle types but the fast-twitch glycolytic fibres had 
50% lower PDK activity in both fed and fasted rats with the changes in PDK4 protein 
expression corresponding to these results. PDK2 protein expression was not different 
between fibre types and was not affected by the 24 h fast (Peters et al. 2001). 
This work was further explored by Sugden et al. (2000) with a longer starvation 
period of 48 h, who demonstrated, using rat soleus and tibialis anterior (66% type lIA, 
32% type lIB, 2% type 1) there was a difference in the up-regulation of PDK2 compared 
to PDK4 between fibre types. They examined pyruvate sensitivity after starvation in the 
two skeletal muscle types and found that as PDK4 content increased, PDHa activity 
became more insensitive to pyruvate activation, confirming what had been predicted from 
the in vivo studies. They concluded that PDK4 was targeted for up-regulation during 
starvation and other dietary perturbations specifically because it made the complex more 
insensitive to pyruvate to divert the 3-carbon units to liver glucose production and away 
from oxidation (Sugden et al. 2000). In rats, high-fat feeding results are similar to the 
adaptations of food-restriction; however, 28 d of high-fat feeding were necessary to elicit 
the same changes in PDK activity as was seen with only 48 h of food-restriction (Orfali et 
al. 1993, Holness et al. 2000). 
Although work on PDK activity and gene expression had been explored in the rodent 
model, little was known about whether a similar response would be observed in human 
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skeletal muscle. Peters et al. (1998) hypothesized that PDK activity would increase on a 
low carbohydrate diet and this would be accompanied by a decreased PDHa activity. The 
authors found a dramatic 3-5 fold increase in PDK activity in human skeletal muscle after 
the low carbohydrate dietary intervention after only 3 days. Decreased insulin and 
increased free fatty acid concentrations were thought to be potential regulators of the 
stable PDK increase (Peters et al. 1998). 
Peters et al. (2001) then examined the protein and mRNA expression ofPDK2 and 4 
over these first 3 days of the low carbohydrate high fat diet. They found that with an 
increase in PDK activity there was a parallel increase of PDK4 protein, while PDK2 
protein was unchanged throughout the first three days. The increase in PDK4 protein was 
maximal within the first day of the dietary intervention, and since there was a linear 
increase of PDK4 activity over the six days, this suggests that perhaps another PDK 
isoform contributed to the continuous increase in PDK activity or there was a change in 
the specific activity of the existing PDK2 or PDK4 isoforms. One of the possibilities for 
this change in activity is that the newly synthesized PDK4 or existing PDK2 improves its 
specific activity as it is bound to the PDH complex core (Peters et al. 2001). Another 
major finding by these authors was that there was a strong correlation between a subject's 
aerobic capacity and the rate of change in PDK activity in the first three days of the diet. 
However, this correlation disappeared by day six. It is possible that the more aerobically 
trained individuals were more sensitive to the decrease in insulin levels which resulted in 
the early increase in PDK activity (Peters et al. 2001). 
Putman et al. (1993) examined the importance of acetyl group accumulation in PDH 
regulation in human skeletal muscle. Putman et al. (1993) used glycogen-depleting 
exercise followed by a low-carbohydrate diet compared to a high-carbohydrate diet 
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perturbation to shift from either fat to carbohydrate utilization. Muscle-depleting exercise 
was completed by the subjects who then consumed either a high-carbohydrate diet or a 
low-carbohydrate diet for three days. Activation of the PDH complex throughout exercise 
at 75% V02 max to exhaustion was attenuated following the low-carbohydrate high fat 
diet suggesting that dietary manipulations can compromise one's ability to fully activate 
PDHa and allow for carbohydrate oxidation (Putman et al. 1993). 
However, initial muscle glycogen content was different between trials in that study, 
as the low-carbohydrate group had lower muscle glycogen levels at rest and during 
exercise than the high-carbohydrate group and glycogen utilization rates were lower 
following the high fat diet. To account for this difference, St. Amand et al. (1999) 
conducted a similar study with focus on maintaining glycogen content by eliminating the 
glycogen-depleting exercise, having a mixed diet group instead of the high carbohydrate 
group, and asking subjects to refrain from physical activity during the dietary 
intervention. The authors found that it was still very difficult to maintain glycogen 
content between the two diet perturbations, even without glycogen-depleting exercise, as 
the low carbohydrate diet still resulted in lower initial muscle glycogen. However, the 
difference in glycogen utilization during exercise was consistent across all time intervals 
for both the control diet and the high fat diet, and muscle pyruvate concentrations were 
similar. Therefore, PDHa activity increased during exercise to a similar extent, 
demonstrating that in spite of the fact that the pyruvate insensitive PDK isoform would be 
higher after the high fat diet, the increased pyruvate production was able to overcome the 
higher PDK activity (St. Amand et al. 1999). 
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c) Changes in PDK2 and 4 with Prolonged Exercise and Exercise Training 
Prolonged exercise is characterized by a shift from carbohydrate as the main fuel 
source to increased fat utilization (Watt et al. 2004) with the PDH complex playing a 
major role in controlling the flux of carbohydrate oxidation. Pilegaard et al. (2000) 
studied the transcription rate and the mRNA responses in human skeletal muscle 
following 4 hours of cycling exercise at 50% maximal 02 uptake. Through muscle 
biopsies, it was found that PDK4 mRNA and transcriptional rate increased after the 4 h 
period. The authors then concluded that PDK4 expression progressively increases with 
exercise duration which could contribute to the progressive inactivation of PDHa. 
However, the authors only measured mRNA content and transcription rate; they did not 
measure the amount of protein, total PDK activity or total PDHa activity (Pilegaard et al. 
2000). Watt et al. (2004) conducted a similar study measuring PDK2 and 4 proteins to 
see whether changes in PDHa activity were due to increased gene expression of the 
isoforms. PDHa activity was decreased and PDK activity was modestly increased, but 
PDK2 and 4 protein concentrations remained unchanged after the 4 h exercise period. 
Therefore, the higher PDK activity was not caused by changes in PDK2 or 4 proteins and 
suggested that there could be an upregulation of specific activity of the existing kinases 
(Pilegaard et al. 2000, Watt et al. 2002, Watt et al. 2004). 
LeBlanc et al. (2004) examined the adaptive responses to repeated exercise training. 
The authors had subjects train on a cycle ergometer at a power output of 75% of their 
maximal 02 uptake for Ih per day, five days a week for a total of 8 weeks. After 1 week 
of exercise, neither total PDH nor PDK activity changed, but by week 8 total PDH 
activity had increased by 31 % while PDK activity had almost doubled. During week 1 
there was also no change in PDK protein expression and by week 8 only the PDK2 
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isoform had increased 1.3-fold. This study suggests that longer-term alterations to energy 
metabolism and energy status favour an up-regulation of PDK2, possibly making this the 
'energy status' -responsive PDK isoform. It is thought that the training-induced adaptive 
increase in skeletal muscle PDK2, which is much more pyruvate sensitive than the other 
isoform, may be used to regulate PDH activation during sub-maximal exercise after 
training to promote increased down-regulation of the complex and enhance fat oxidation, 
but allow for increased activation of the complex, when necessary, with higher intensity 
exercise and increased glycolytic flux (LeBlanc et al. 2004). 
Physiological Changes of the PDKI Isoform 
Currently, there is very little known about the PDK1 isoform, but it is present in 
high levels in the heart, with lower levels found in skeletal muscle, liver and pancreas 
(Patel and Korotchkina, 2006). Its catalytic activity is second only to that of the PDK3 
isoform which is found in such small quantities in rodent tissue that it has yet to be 
accurately measured (Gudi et al. 1995, Bowker-Kinley et al. 1998). The PDK isoforms 
differ in their E1-a phosphorylation site specificity, and while all four PDK isoforms 
have the ability to phosphorylate sites 1 and 2, only the PDK1 isoform can phosphorylate 
site 3 (Korotchkina and Patel, 2001, Kolobova et al. 2001). Therefore, PDK1 has the 
ability to make the complex more difficult to dephosphorylate or activate by the PDPs. 
Peters et al. (2001) were the first to examine the changes in PDK1 protein 
concentrations in three skeletal muscle fibre types. The expression of the PDK1 isoform 
was found to be much lower in glycolytic muscles compared to oxidative muscle, and 
PDK1 protein remained unchanged in response to a 24 h fast (Peters et al. 2001). The 
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mRNA expression of all four PDK isoforms in human skeletal muscle tissue after both 15 
and 40 hrs of fasting was consistent with these data from rodents showing the PDKI 
isoform to remain unaffected (Spriet et al. 2004). In human skeletal muscle the 
mitochondrial protein concentrations of PDKI and 4 were found to be only -10 % of the 
PDK2 content, which is abundantly expressed (LeBlanc et al. 2004). Although there was 
an increase in PDK2 protein after both 1 and 8 wks of exercise training, there was no 
change seen in the small amount of PDKI protein (LeBlanc et al. 2004). These results 
consistently demonstrate that the PDKI isoform is unaffected by perturbations that have 
shown to alter the expression of both PDK2 and 4. New information using total RNA 
prepared from human (abdominal muscle) rat (heart, abdominal muscle, spleen, liver 
brain, kidney, testis and lung) and mouse (liver and C2C12 cells) (Huttemann et al. 2001) 
and cultured mouse and human (Hep3B, HeLa, Hct116 and A594) cells (Fukuda et al. 
2007), regarding the effects of hypoxia, has shown that during low oxygen conditions, the 
PDKI isoform has been shown to be upregulated by hypoxia-inducible factor 1 (HIF-l) 
(Semenza, 2007). 
PDK2 and PDK4 Knockouts 
The term "knockout" is used to explain the deletion or inactivation of a gene in a 
cell in order to determine what role the gene plays in the organism as a whole. Jeoung et 
al. (2006) created and tested these "knockout" mice for the PDK4 gene (PDK4 KO). The 
mice were lacking PDK4 in order to better understand the role that this protein normally 
played in PDH complex regulation with nutritional challenges such as prolonged 
starvation. Starvation for 48 h induced an increase in PDK4 protein content of wild-type 
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(WT) mice, as expected, but it was shown to have no effect on the already large amount 
of PDK2 protein in PDK4 KO mice. Therefore, there was no evidence found for the up-
regulation of PDK2 to compensate for lack of PDK4 in diaphragm, while in 
gastrocnemius muscle of starved PDK4 KO mice, the amount of PDK2 protein was 
actually lower than in wild-type mice. The PDH complex was more active in the 
diaphragm of starved PDK4 KO mice (ie. higher PDHa activity), compared to starved 
wild-type, indicating that PDK4 would normally playa stronger role in down-regulation 
of the complex during starvation, while total PDK activity was not measured (Jeoung et 
al. 2006). Higher PDHa activity suggests that in PDK4 KO mice during starvation there 
is an increase in the oxidative disposal of glucose, through increased flux through the 
PDH complex, which would positively affect whole body glucose homeostasis. 
In a more recent study, PDK4 KO mice were used to study glucose homeostasis 
in diet-induced obesity compared to WT mice, to establish the role of PDK4 in the 
obesity-induced hypoglycaemia by promoting increased muscle glucose disposal (Jeoung 
et al. 2006). Both WT and PDK4 KO mice were fed a high-fat diet (16% protein, 59.5% 
fat, 24.5% carbohydrate) for 18 weeks in order to induce obesity, while control groups 
for both PDK4 KO and WT mice were fed a chow diet. As expected, high-fat feeding 
caused obesity, fasting hyperglycaemia, increased fasting serum insulin levels, fasting 
glucose intolerance and insulin resistance in the WT mice. There was also an increase in 
PDK4 expression in gastrocnemius of WT mice which is consistent with previous studies 
involving the short-term effects of a high-fat diet (Holness et al. 2000). PDK4 KO mice 
also became obese from high-fat feeding and showed similarly elevated insulin levels. 
However, they had significantly lower fasting blood glucose levels and slightly improved 
glucose tolerance and insulin sensitivity. This study demonstrates that the absence of the 
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PDK4 isoform improved the negative effects of diet-induced obesity, promoting lower 
blood glucose and improved glucose tolerance suggesting that PDK4 could be a target for 
therapeutic models of diabetes. 
Recently in our lab PDHa activity was examined at rest and at the onset of low 
and high intensity exercise conditions in incubated mouse extensor digitorum longus 
(EDL) muscles from PDK4 KO and WT mice (Martin et al. 2007). PDHa activity was 
higher with increased muscle stimulation intensity in both PDK4 KO and WT mice, but 
PDHa was higher at rest and during contraction at intensities of 10 and 40 Hz in PDK4 
KO mice [Fig. 3]. In fact, at 40 Hz stimulation, which evoked -50% PDHa activation in 
WT, PDHa was almost fully activated in PDK4 KO. This demonstrates that in the 
absence of PDK4, even though there may be the same amount of PDK2 present, the 
remaining kinase activity cannot appropriately modulate PDHa activity and implicates a 
role for PDK4 in 'down regulating' or 'fine-tuning' the activation of the complex during 
muscle contraction under normal conditions. 
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Figure 3. Previous work examining PDHa activity in incubated EDL muscles in wild-
type mice and PDK4 knockout mice (PDK4KO) at Rest and at 10 Hz and 40 Hz 
stimulation. PDHa activity was higher in muscles from PDK4KO mice at Rest and both 
contraction intensities (Martin et al. 2007). 
SUMMARY 
PDK2 is the most abundant PDK isoform in skeletal muscle, and allosterically it 
is the most sensitive isoform to intra-mitochondrial pyruvate concentrations. The main 
role of PDK2, and other PDKs, is to phosphorylate and inhibit the PDH complex. In 
general, PDK2 expression is relatively unchanged with dietary challenges such as 
starvation and a high fat diet, both of which have shown to increase the expression of 
PDK4. However, with exercise training, when the reliance on fat is preferable, it is PDK2 
that increases rather than PDK4. These results, as well as the high sensitivity of PDK2 to 
pyruvate concentrations, suggest that PDK2 plays an important role in decreasing PDHa 
activity during exercise after training and promoting fat oxidation, while allowing for 
PDH activation when needed, such as with an increased workload. However, the role that 
PDK2 plays in activating the PDH complex during muscle contraction is currently 
unknown. 
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CHAPTER 3 
Statement of the Problem 
1. Currently there is limited research on the most abundant PDK2 isoform and the 
subsequent effect of the deletion of this gene on the up regulation and activity of the other 
two skeletal muscle-predominant PDK isoforms 1 and 4 and PDH components El-a and 
E2. 
2. The role that PDK2 plays in regulating PDHa activity during an acute bout of muscle 
contraction is unknown. 
Purpose 
The purpose of this study was to determine the role that PDK2 plays in the regulation of 
PDHa activity at rest and during low intensity and moderate intensity muscle contraction 
in isolated skeletal muscle from PDK2 KO mice compared to their WT counterparts. 
Hypothesis 
The absence of the most abundant PDK2 isoform would result in an increase in PDHa 
activity in PDK2 KO mice when compared to WT at rest and during both stimulation 
conditions, with possible upregulation of PDK4 as a compensatory strategy. It was not 
expected that ablation of PDK2 would alter the PDH subunits. 
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CHAPTER 4 
METHODOLOGY 
Animals 
Twenty-two C57BLl6J mice (11 PDK2 knockouts and 11 of their WT littermates) 
generously supplied by Dr. Robert Harris (Dept of Biochemistry and Molecular Biology, 
Indiana University School of Medicine) were used for this experiment. PDK2 KO and 
WT mice weighed 27 ± 5g and 25 ± 2g respectively and ranged in age from 9 - 12 
months, both WT and PDK2 KO were age matched, one WT and one PDK2 KO 
experiment was performed simultaneously. The animals were housed in the Brock 
University Animal Care Facility for at least one week prior to being used in our studies in 
a controlled environment with a 12:12 h reversed light-dark cycle to be sure that they are 
fully acclimatized to their new surroundings. Animals were fed Purina Rat Chow 
(Ralston Purina Co.) ad libitum and were not fasted. All experimental interventions were 
formally approved by the Brock University Animal Care and Utilization Committee and 
conformed to all of the Canadian Council for Animal Care guidelines (AUPP 05-12-01). 
Experimental Protocol 
All animals underwent the same surgical and bath incubation protocols, but 
seperate incubations for muscle phosphagen determination and PDHa activity were 
completed. Animals were anesthetized with an intreperitoneal injection of sodium 
pentobarbital (6 mg /100 g body wt.) and EDL and hindlimb muscles were removed. The 
hindlimb muscles were freeze-clamped within 10 s of their removal, while each EDL 
muscle had a suture placed on each tendon and then was immediately placed in an organ 
bath which was filled with fully oxygenated liquid Sigma medium 199 (M4530, see 
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appendix for detailed composition) and suspended at a resting tension of Ig of force. 
Muscles were allowed to incubate at rest for 30 min to equilibriate [Fig 4.]. After the 
initial incubation, the muscles were either removed within 10 s and freeze-clamped (rest) 
or stimulated with tetanic contractions every 5 s for a duration of 3 min at 10Hz (low 
intensity) or 40 Hz (moderate intensity), then removed within 10 s and freeze-clamped 
for further analysis [Fig 5.]. 
EDL 1-1 -----:j"f'o4'------------1 
30min 
REST 
• phosphagen 
determination 
Figure 4. Schematic diagram of muscle phosphagen protocol. EDL muscles were 
excised and placed in an organ bath. The muscle was incubated for 30 min at rest. 
Muscles were freeze-clamped « 1 Os) and used for phosphagen determination. 
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Figure 5. Schematic diagram of stimulation protocol. EDL and hindlimb muscles were 
excised. Mitochondria from the hindlimb was used for PDK activity and Western blotting 
for the PDKs, PDH components and COXIV protein determinations. EDL muscles were 
placed in an organ bath and attached to a transducer. Optimal length and voltage were 
determined after the muscle was incubated for 30 min at rest. Resting muscles were 
freeze-clamped «lOs) and used for PDHa activity determination. Muscles not used for 
rest went through the 3 min stimulation protocol at either 10 or 40 Hz. Muscles were 
freeze-clamped «lOs) and used for PDHa activity determination. 
Force Acquisition 
Optimal Stimulus Voltage and Optimal Length Determination 
Before the stimulation protocol began, optimal stimulus voltage and optimal 
length (Lo) were determined by a force transducer (Grass Model FT03 with P11 T 
amplifier). To establish optimal stimulus voltage, the muscle was suspended at 19 of 
resting tension and twitched, starting at 10 V with continuing single twitches until a 
plateau in force production was observed (-50-70 V). 
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Stimulation Protocol 
The stimulation protocol consisted of a 200 ms train duration, a train rate of 0.2 
trains per second and a stimulation frequency of 10 Hz or 40 Hz. Total contraction time 
was 3 min. All contraction data was recorded using a Grass Polyview Data Acquisition 
and Analysis System (West-Warwick, RI) and analyzed using Polyview Reviewer (Grass 
Polyview Data Acquisition and Analysis System; West-Warwich, RI). 
Establishing a Force-Frequency Curve 
Low and moderate stimulation was chosen to elicit a range of PDHa activities that 
would be -50% of maximal PDHa activity. Pilot experiments were completed to 
establish a force-frequency curve [Fig. 6] (Martin et al. unpublished results) used to 
determine the frequencies required for low and moderate stimulation in relation to PDHa 
activity. Muscles from male C57BLl5J (Charles River, St. Constant, PQ) mice, (n = 5) 
were stimulated from 1-40 Hz and these frequencies were plotted against force 
production relative to maximal force, which was achieved at 150 Hz (FlFmax). A 
frequency of 10 Hz was able to stimulate the muscle to approximately 20% of its 
maximal force, and was therefore selected as the low intensity frequency. However, a 
frequency of 40 Hz stimulated the muscle to contract at approximately 55% of its 
maximal force, and therefore was selected as the moderate intensity frequency. 
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Figure 6. Force-frequency curve. Relative muscle force produced at various stimulation 
frequencies (Martin et al. 2007). 
Mitochondrial Extraction 
Intact mitochondria were extracted from mixed mouse hindlimb muscle by 
differential centrifugation as previously described by Jackman et al. (1996) and Makinen 
et al. (1968). Minced muscle was homogenized using a glass-on-glass Potter 
homogenizer in a buffer 20 vol of a buffer containing 100mM KCl, 40mM Tris-HCI, 
IOmM Tris base, 5mM magnesium sulfate, ImM EDTA, and ImM ATP (pH 7.5). The 
supernatant was retained after centrifugation at 700 g for 10 min and spun at 14000 g for 
10 min. The supernatant was removed, but discarded, leaving the mitochondrial pellet 
which was washed, resuspended and centrifuged twice (7000 g) in 10 vol of 100mM KCl, 
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40mM Tris-HCI, lOmM Tris base, ImM magnesium sulfate, O.lmM EDTA, and 0.25mM 
ATP (pH 7.5). The first wash buffer included 1 % bovine serum albumin, and the second 
was protein free. The final mitochondrial pellet was resuspended in a volume 
corresponding to 1 j..ll /1 mg fresh muscle extracted. The final buffer contained 220 mM 
sucrose, 70 mM mannitol, 10 mM Tris-HCl, and 1 mM EDTA (pH 7.4). All procedures 
were completed at 0-4°C. 
PDHa Activity 
PDHa activity was measured according to Constantin-Teodosiu et aI. (1991) as 
modified by Putman, et al. (1993) The homogenizing buffer to measure PDHa activity 
(PDH in the active form) containing 200 mM sucrose, 50 mM KCI, 5 mM MgCh, 5 mM 
ethylene glycol tetraacetic acid (EGTA), 50 mM Tris HCI, 50 mM NaP (to inhibit the 
PDH phosphatase reaction), 5 mM dichloroacetate (to inhibit the PDH kinase reaction) 
and 0.05% Triton X-IOO (pH 7.8), was placed into a homogenizing mortar (100 j..ll) and 
tared. Frozen muscle (3-10 mg wet) was added to the mortar, and its weight was 
recorded. Additional buffer was added to dilute the muscle to 30 volumes. The 
homogenization of the sample was initiated with gentle twisting of the pestle by hand. All 
homogenization was done with the sample on ice, and the movements were not hard 
enough to cause "bubbles" which could denature proteins and inactivate the enzyme. 
Grinding continued with a motor driven glass pestle for 30 s at -20-30 rpm, also on ice. 
The homogenized sample was stored in liquid N2 in an eppendorf tube prior to PDHa 
activity determination. 
PDHa activity was measured as the rate of acetyl-CoA production. Muscle 
homogenate (30 j..ll) was added t0720ml of reagent mixture containing 144.4mM Tris, 
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0.72mM EDTA, 1.44mM MgClz, 39 mM NAD, 13mM CoASH, 13mM TPP at 37°C in a 
12x75 glass tube warmed in a block heater. The reaction was initiated with 26mM 
pyruvate (30 III of ImM solution) and 200 III aliquots was removed at precisely timed 
intervals (1, 2, and 3 min) and placed into 40 III of 0.5N perchloric acid (PCA) to stop the 
reaction. Samples were neutralized with 10 III of 1M potassium carbonate (K2C03) after 
5 min following reaction with PCA. The neutralized extracts were stored at -80°C for 
analysis of acetyl-CoA concentration. 
Acetyl-CoA concentration was measured in timed samples as outlined by 
Cederblad et al (1990) according to the citrate synthase reaction with radioactively 
labeled oxaloacetic acid to produce labeled citrate. Acetyl-CoA standards were prepared 
(0,40nM, 125nM, 250nM, 375nM and 500nM) and 10 III of each sample was added to 
200 III of water. The 14C-oxaloacetic acid (OAA) substrate needed for the reaction was 
prepared according to the glutamate oxaloacetate transaminase reaction (GOT) ( 14C_ 
GOT 
oxaloacetate + glutamate • 14C-aspartate + 2-oxyoglutarate) 14C-OAA was added 
to the samples and the reaction was started with citrate synthase and allowed to proceed 
at room temperature for 20 min. N-ethylmaleimide (NEM) (30 mM) was added to bind 
to the 14C-citrate produced and promote the forward citrate synthase reaction. 14C-citrate 
produced in the reaction was separated from 14C-oxaloacetate as follows: 14C_ 
oxaloacetate was converted back to 14C-aspartate through the reverse transamination 
reaction. The resultant 14C-aspartate was separated from 14C-citrate through mixing with 
acidic Dowex resin (1.0 ml) and centrifuged (Beckman-Coulter Allegra 21R; Fullerton 
CA) at -3000 rpm for 2 min. An aliquot of the supernatant containing 14C-citrate was 
pipetted into scintillation vials and counted using a liquid scintillation counter (Beckman-
Coulter LS; Fullerton, CA). 
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PDK Activity 
Fresh skeletal muscle, from previously extracted mitochondria, was used and 
homogenized. The final pellet was resuspended in a 6-fold carbonylcyanide m-
chlorophenylhydrazone (CCCP) buffer containing, 20 rnM Tris-HCl, 120 mM KCl, 2 
rnM EGTA, 5 mM potassium phosphate (KH2P04) to decrease A TP concentration to 
zero, resulting in compete conversion of PDH to the active form. This mixture was 
incubated at 30°C for 20 min, and then the mitochondria was pelleted at 7000 g for 10 
min to pellet down the portion of the mitochondria containing the activated PDH 
complex. The top of the eppendorf tube containing the pelleted mitochondria was 
perforated and flash frozen into liquid N2 to be later assayed for PDK activity. 
On the day of analysis, the pellet was thawed and completely resuspended in 30 
mM KH2P04, 5 rnM, EGTA, 5 rnM, DTT, 1 % bovine serum albumin (BSA), 1 mM 
tosyl-Iysyl-chloro-methyl-ketone (protease inhibitor) 0.1 % Triton, and 2 III /1 mg 
oligomycin B (FI-ATPase inhibitor) for a total of 1.0 ml. The suspension was freeze-
thawed once more to ensure that the mitochondria were broken, and then kept in liquid 
N2 until analysis. Magnesium ATP was added to the remaining suspension, bringing the 
concentration to 0.3 mM, and timed samples were taken every 30 s for 4 min at 30°C as 
previously described Fatania et al. (1986) and Vary et al. (1991). 
PDK activity was measured as the apparent first-order rate constant of the 
inactivation of PDH (min-I), or the slope of In[%(PDHa activity with ATP addition)/(total 
PDH without ATP addition)] vs. time. The slope (1 st order rate constant) was determined 
by a regression analysis of the line. 
29 
Western Blotting 
All Western blotting was performed on extracted mitochondria as previously 
described (LeBlanc et al. 2004). Protein concentrations were measured using a Bio-Rad 
Protein Assay Reagent (BioRad, Hercules, CA) and detected on a microplate reader at 
595nm wavelength (Biotek Instruments, Winooski, VT, USA). 
Mitochondria were diluted to final protein concentration of 1.0 Ilg / III in 50 mM Tris-
HCL, pH 6.8, containing 2% SDS, 0.1 M dithiothreitol, 0.1 % bromophenol blue, 10% 
glycerol, and a protease inhibitor cocktail (1 mM benzamidine, 0.1 mglml trypsin 
inhibitor, 0.1 mM tosyl-Iysyl-phenylmethlketone) as previously described by Peters et al. 
(2001). Samples were then solublized by boiling for 5 min and then cooling for 5 min. 
Standard SDS-PAGE electrophoresis was performed with 12% separating and 4% 
stacking gels for all mitochondrial samples, PDK1, 2, 4, COX IV as well as PDH 
component determinations; E1-a and E2 (10 Ilg of mitochondrial protein per lane). 
Proteins were separated through electrophoresis and immersed in a running buffer 
containing 250mM Tris base, 1.92M glycine, and 0.1 % SDS. The proteins were then 
transferred onto polyvinylidene fluoride (PVDF) (Millipore Corporation; Billerica, MA, 
USA) using the tank method of electrophoretic transfer (Bio-Rad, CA, USA) with a 
transfer buffer containing 34.8 mM Tris base, 31.2 mM glycine, 0.03% (w/v) SDS, and 
20% (v/v) absolute methanol as previously described (LeBlanc et aI., 2004). Membranes 
were then incubated in TBST buffer (20 mM Tris base, 137 mM NaCl, 0.1 % (v/v) Tween 
20, pH 7.5) and 5% dry milk for 1 h to block all non-specific binding sites. Membranes 
were then incubated overnight in 10 ml 5% milk-TBST containing 10 III monoclonal 
antibodies against: PDK1 (Abeam, AB 47987, Cambridge, MA, USA); PDK 2 (Abgent, 
AP 7039b, San Diego, CA, USA); PDK 4 (Abgent, AP 7041b, San Diego, CA, USA); 
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COX IV (Mitosciences, MS 407, Eugene, OR, USA); Ela (Molecular Probes, A 21323, 
Eugene, OR, USA) and E2 (Molecular Probes, A 21325, Eugene, OR, USA) antibodies. 
The membranes were washed with TBST, 3 times for 5 min each, and then incubated 
for 1 h in 10 ml 5% milk-TBST containing 0.5 III goat anti-rabbit IgG (HRP-conjugated 
horseradish peroxidase (HRP), Santa Cruz Biotechnology, CA, USA) for PDK 2 and 4, 
bovine anti-goat IgG HRP (Santa Cruz Biotechnology, CA, USA) for PDK 1, anti-mouse 
HRP for COX IV, Ela and E2, as described by LeBlanc et. aI., 2004. COX IV was used 
as a loading control. Membranes were again washed with TBST, 3 times 5 min each, and 
incubated for 1 min with extremely sensitive enhanced chemiluminescent substrate 
Chemiglow (Alpha Innotech, San Leandro, CA, USA) to develop the immunoblots. Light 
from the antibody-antigen complexes were visualized the use of Pluro Chern 5500 (Alpha 
Innotech, San Leandro, CA, USA). Relative densities were quantified (ImageJ, National 
Institute of Health) and results are expressed as the intensity of the band in arbitrary units. 
Determination of Phosphagen Concentrations 
Consistent with current literature, phosphagen concentrations were examined to 
determine muscle viability (Antolic et ai. 2007). The extraction process was completed 
after the frozen EDL muscles were freeze-dried (Labconco Corporation; Kansas City, 
MO, USA). Once the water from the EDL muscles was completely removed, the tendons 
and connective tissue were teased apart from the muscle tissue, and then the muscle 
tissue was powdered. The powdered tissue was then weighed in a pre-weighed micro 
centrifuge tube and placed on ice. Once cold, 150-250 vol. of pre-cooled 0.5 M perchloric 
acid (PCA) was added to the powdered tissue and centrifuged (Beckman Coulter, Allegra 
21; Palo Alto, CA, USA) at 4°C at 15000 g for 10 min to precipitate debris and remove 
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enzymes that can influence the metabolite concentration. The supernatant was removed 
and potassium bicarbonate (KHC03) was added. Finally, the sample was centrifuged at 
4°C at 15000 g for 10 min and the supernatant was removed and stored at -80°C until 
assayed for phosphagens and lactate. Muscle phosphagen concentrations were 
determined by flurometric techniques according to procedures described by Harris et al 
(1974) and modified by Green et al. (1987). Each sample was analyzed in triplicate. For 
adenosine triphosphate (ATP) and phosphocreatine (PCr) concentration measurements a 
reagent containing 0.1 M Tris buffer (pH 8.1), 1M MgClz, 0.5 M DTT, 100 mM glucose, 
50 mM nicotinamide adenine dinucleotide phosphate (NADP) and glucose-6-phosphate 
dehydrogenase (G-6-P-DH) (Sigma G-5760) was first added and analyzed at sensitivity 
of 80, excitation setting 340 and emission setting 460, with the Multi-Detection 
Microplate Reader (Bio-Tek Instruments, Winooski, VT, USA). The second and third 
reactions were initiated with the addition of hexokinase and then the addition of 
phosphocreatine kinase and adenosine diphosphate. Both were analyzed and read at the 
same previously stated settings. All measurements were made fluorometrically on a 
microplate reader (Bio-Tek Instruments, Winooski, VT, USA) at an excitation setting 340 
nm and emission setting 460 nm, creating a baseline reading. 
Statistics 
PDHa activity was analyzed with SigmaStat, (Port Richmond, CA) as a two-way 
ANOVA (stimulation frequency; WT or KO). When significance was detected, means 
were compared using a Tukey's post hoc test. For protein contents and total PDK 
activity data, an unpaired two-tailed t-test was used. Significance was accepted at p< 
0.05. 
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CHAPTERS 
RESULTS 
Muscle Viability 
Viability of muscle incubations was confirmed in our hands by measuring 
phosphagen concentrations (ATP and PCr) in a series of independent 30 min resting 
incubations (n=3). PCr was 80±2 and ATP was 25±2 mmol/kg dry muscle respectively. 
PDHa Activity 
As expected, there was a main effect for higher PDHa activity with muscle 
contraction for both WT and PDK2 KO. There was also a main effect for lower PDHa 
activity with contraction in the PDK2 KO muscles compared to WT [Fig. 7]. 
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Figure 1. PDHa activity during rest, low and moderate intensity contraction in WT and 
PDK2 KO mice. PDHa activity was measured on whole muscle homogenates and is 
reported in units of mmolmin-l.kg wet muscle-I. *, main effect for lower PDHa activation 
in PDK2 KO muscles vs. WT,p < 0.05. t, main effect for stimulation to increase PDHa 
activationp < 0.05. 
Total PDK Activity 
Total PDH kinase activity was -4-fold greater in WT mice in comparison to 
PDK2 KO (p < 0.05) [Fig. 8]. 
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Figure 8. PDK activity in WT and PDK2 KO hindlimb muscle mitochondria. PDK 
activity was measured on isolated intact mitochondria and is reported as first-order rate 
constant for ATP-dependent inhibition ofPDHa (units are min- ). n = 5 in each 
group.*Significantly different from WT, p < 0.05. 
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PDKl,2 and 4 Isoform Content 
Western blot analysis was used to determine the protein content of the three PDK 
isoforms, two PDH subunits El-alpha and E2, and the mitochondrial marker COXIV in 
both WT and PDK2 KO. PDK2 protein was not detected by Western blot analysis in 
skeletal muscle extracts ofPDK2 KO [Fig. 9]. The amount ofPDK4 protein content was 
similar in both WT and PDK2 KO (p = 0.19) [Fig. 10], while PDKI protein showed a 
44% increase (p < 0.05) in the muscle mitochondria from PDK2 KO [Fig. 11]. 
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Figure 9. PDK2 protein content in WT and PDK2 KO mice. Inset, representative protein 
blots for WT (wild type) and PDK 2KO (PDK2 knockout) mice. Values are means ± 
S.E.M. with n = 6 in each group. 
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Figure 10. PDK4 protein content in WTand PDK2 KO mice. Inset, representative 
protein blots for WT (wild type) and 2KO (PDK2 knockout) mice. Values are means ± 
S.E.M. with n = 5 in each group, p = 0.19. 
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Figure 11. Representative Western blot of PDKI protein content in WTand PDK2 KO 
mice. Inset, protein blots for WT (wild type) and 2KO (PDK2 knockout) mice. Values 
are means ± S.E.M. with n = 5 in each group. *Significantly different from WT, p < 0.05. 
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PDH complex subunits and COXIV content 
The deletion of the PDK2 isoforrn also affected the protein content of El-a 
protein showing a 32% increase (p < 0.05) [Fig. 12]. No significant difference was found 
in E2 protein content between WT and PDK2 KO mice, although there was a trend 
towards slightly increased E2 (p = 0.112) [Fig. 14]. This did not reflect a generalized 
change in mitochondrial oxidative capacity, since eOXIV protein was not higher in 
PDK2 KOs (p = 0.3301) [Fig .13]. 
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Figure 12. E1-aprotein content in WTand PDK2 KO mice. Insert, protein blots for WT 
(wild type) and 2KO (PDK2 knockout) mice. Values are means ± S.E.M. with n = 5 in 
each group. *Significant difference from WT,p < 0.05. 
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Figure 13. COXIV protein content in WT and PDK2 KO mice. Inset, representative 
protein blots for WT (wild type) and PDK 2KO (PDK2 knockout) mice. Values are 
means ± S.E.M. with n = 5 in each group,p = 0.3301. 
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Figure 14. E2 protein content in WT and PDK2 KO mice. Inset, representative protein 
blots for WT (wild type) and PDK 2KO (PDK2 knockout) mice. Values are means ± 
S.E.M. with n = 5 in each group, p = 0.112. 
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CHAPTER 6 
Discussion 
This study describes the effects of the deletion of the PDK2 isoform in mice on 
PDHa activity during contraction, the relative expressions of the remaining PDKs and 
their total combined activity in skeletal muscle. As well, muscle expression of individual 
subunits of the PDH complex and the oxidative capacity of these genetically modified 
mice were examined. The major finding was that PDHa activity was lower during muscle 
contraction in the PDK2 KO mice compared to the WT mice, in spite of the fact that 
these mice lack the most abundant PDK isoform and have markedly lower total PDK 
activity. There was significantly increased expression of PDK1 protein (but not PDK4 
protein) which could account for the decreased PDHa activity in PDK2 KO mice. In what 
appears to be an adaptive response, there was a 32% increase in E1-a protein expression 
in PDK2 KO mice, but this did not reflect a generalized increase in oxidative capacity. 
Model Viability 
The viability of the muscle incubations was confirmed through the analysis of 
phosphagen concentrations in frozen EDL muscles from separate 30 min incubations. In 
our hands, ATP and per values were similar to normal resting muscle values, confirming 
that at rest the viability was not compromised after the muscles were surgically removed, 
placed into the organ bath. EDL muscle ATP and per were found to be 2S±2 and 80±2 
mmollkg dry muscle respectively, which is consistent with previous work in resting rat 
EDL muscle (ATP and per levels of - 30 and 77 mmollkg dry muscle respectively; 
Antolic et al. 2007). The viability of the mouse EDL muscle incubation procedure has 
been previously well established (as reviewed by Bonen et al. 1994). For these types of 
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studies, mouse EDL muscle is an easily isolated fusiform muscle, and has a small 
diameter in mature animals «lmm) therefore allowing consistent and rapid O2 diffusion 
during incubation. Although the muscle has a small diameter, the temperature of the 
incubation is a major viability determinant. Specifically, at higher, more physiological 
temperatures (eg. 37°C) muscle oxygen consumption demand increases but the rate of 02 
diffusion does not increase proportionally (Bonen et aI1994). This is amplified during 
contraction by an additional increase in the rate of metabolism and 02 consumption from 
the contracting muscle. Therefore, to counteract these potential problems and ensure a 
viable muscle, the muscle incubations were completed at 25°C at which temperature the 
diameter of the mouse EDL is well below the critical thickness necessary to support 
oxygen consumption. While the critical thickness of mouse EDL muscles for 02 diffusion 
at higher temperatures is 1.94 mm (Bonen et al. 2007), the calculated maximum diffusion 
distance at 25°C is 0.3 mm (Barclay, 2005), and therefore 02 diffusion would be capable 
of supporting the muscles metabolic rate during contraction. 
For this study, both the mouse EDL and hindlimb were analyzed to determine the 
combined effect of the deletion of the PDK2 isoform had on PDHa and total PDK 
activity as well as the protein contents of the PDK isoforms and the PDH components 
during muscle contraction. Both of these muscles were used in this study because the 
small size of the EDL muscle only allowed for the measurement of PDHa activity, while 
the hindlimb was used for the protein determinations and total PDK activity. The fibre 
type composition of both the EDL and the hindlimb in the mouse are similar, with the 
EDL primarily composed of type IIa and lib fibres with a small amount of type I fibres 
(Crow and Kushmerick, 1982) while the hindlimb is composed of primarily type lib 
fibres, with a small amount of type lId and IIa fibres respectively (Hamalainen and Pette, 
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1992). Both muscle groups have a similar fibre type composition, with the EDL having 
slightly more fast glycolytic fibres while the hindlimb contains more fast oxidative fibres. 
Due to the similarity in fibre type composition of both the EDL and the hindlimb these 
results show that in both muscles there are similar generalized adaptations seen as a result 
of the deletion of PDK2. 
PDHa and total PDK activity 
Our results confirm, through Western blotting, that PDK2 KO mice did not have 
any PDK2 protein present in comparison to WT mice. PDK2 is the most abundant 
isoform in skeletal muscle and is highly sensitive to pyruvate inhibition but demonstrates 
a higher sensitivity to the energy status of the cell (Gudi et ai. 1995, Popov, 1997, 
Bowker-Kinley et al. 1998). As such, PDK2 has been referred to as the "energy 
responsive" isoform because of its role in decreasing PDHa activity during sub-maximal 
exercise after aerobic training (LeBlanc et al. 2004). Therefore, it was not surprising that 
total PDK activity was found to be -4 fold greater in WT than PDK2 KO. 
The diaphragm of starved PDK4 KO mice was shown to have higher PDHa 
activity (Jeoung et ai. 2006). These results are consistent with our findings that PDHa 
activity was higher at rest and both stimulation frequencies in PDK4 KO EDL muscles 
(Martin et ai. unpublished). Therefore, given the lower total PDK activity, our hypothesis 
was that PDHa activity would be even higher in PDK2 KO mice. We believed that the 
removal of the PDK2 isoform would allow less phosphorylation of the PDH complex and 
result in a higher active component at a given stimulation intensity (Gudi et aI., 1995, 
Sugden and Holeness, 2003). Predictably, a main effect for stimulation frequency (and 
higher contraction intensity) to increase PDHa activation was observed, which is 
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consistent with other work that generally shows that the activation state of the PDH 
complex parallels exercise intensity (Howlett et al. 1998 , Constantin-Teodosiu et al. 
1991). However, quite surprisingly we also observed lower PDHa activation in PDK2 
KO muscles in comparison to WT. This suggests that the activation of the complex 
during muscle contraction is more reliant on the collective kinetic properties of the 
population of the PDK isoforms than on the maximal total PDK activity available to 
down-regulate the complex. 
The allosteric regulators of the PDH complex through PDPI is Caz+ and the 
PDKs are ATP/ADP, NADHlNAD+, and acetyl-CoNCoA ratios and pyruvate 
respectively. At a given stimulation frequency, the mitochondrial Caz+ concentration 
would be similar, therefore the lower PDHa activation in PDK2 KO mice could be 
caused by the relative response of the remaining PDK isoforms to the present allosteric 
effectors. While both PDKI and PDK4 are expressed in generally very low 
concentrations in skeletal muscle, they are hugely different in their responses to allosteric 
effectors, particularly energy charge, acetyl-CoA and pyruvate concentrations, which are 
changed during contraction. As such, it would be important to fully understand what 
changes, if any, were occurring in the expression of these two isoforms in the PDK2 KO 
mIce. 
PDKI and PDK4 protein content 
In musc,Ie of PDK2 KO mice PDKI protein content increased 44%, while PDK4 
protein was unaltered. PDK4 has been shown to be upregulated during many dietary 
perturbations (Orfali et al. 1993, Wu et al. 1998, Wu et al. 1999) while PDKI protein 
expression has remained unchanged throughout all physiological perturbations studied 
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thus far (Peters et al. 2001, Spriet et al. 2004., LeBlanc et al. 2004), although increased 
PDKI has been observed recently during hypoxic conditions (Semenza, 2007). Even 
though the protein content of PDK4 remained unchanged, the exposure of the allosteric 
properties of PDK4 (particularly its insensitivity to pyruvate inhibition) could be a 
possible contributor to the lower PDHa activity observed during contraction in PDK2 KO 
mice. 
To our knowledge, this the first study to report an increase in PDKI content in the 
absence of hypoxia. PDKI has a specific activity of about 30-50% lower than PDK3 
(Bowker-Kinleyet al. 1998), however, its activity is considerably higher than both those 
of PDK2 and PDK4. Of the four isoforms, both PDKI and PDK2 were found to be about 
70% similar in primary structure (Bowker-Kinley et al. 1998). PDK2 is known to be 
highly sensitive to pyruvate inhibition (Bowker-Kinley et al1998; Sugden and Holness 
2001), while PDKI is even more sensitive to ADP inhibition than PDK4 (Bowker-Kinley 
et alI998). PDKI is also the only isoform that can phosphorylate site 3 of the El-a 
subunit (Korotchkina et al. 1995). This is significant because PDHa activity of the 
complex can be sufficiently decreased or inhibited through the phosphorylation of only 
site 1, while the phosphorylation of sites 2 and 3 effectively cause the PDH complex to 
be harder to dephosphorylate or activate by the PDPs. Thus, the increase in PDKI protein 
content could increase the phosphorylation of site 3, making it more difficult for the 
PDPs to activate the complex, and causing the lower PDHa activity in PDK2 KO muscle 
with the contraction stimuli. This underscores the importance of the kinetic properties of 
the population of isoforms rather than the total activity, since even with the absence of 
PDK2 and lower total PDK activity, PDHa activity is still lower in PDK2 KO mice. 
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These results can be explained by the kinetic properties of PDK4 and possibly even more 
by the increase in PDKI content, since PDKI would be a potent inhibitor of the complex. 
PDH·El·u and PDH·E2 protein content 
Western blotting to detect the PDH components El-a and E2 demonstrated that 
there was a 32% higher El-a protein content in PDK2 KO muscle compared to WT, 
while E2 content was unchanged. The higher El-a protein content without alterations in 
E2 is consistent with what has been previously observed in human skeletal muscle with 
endurance training (LeBlanc et al. 2004, Love et al. 2009, unpublished results). Our work 
is consistent with their suggestion that because the El-a subunit is rate-limiting for the 
decarboxylation of pyruvate to acetyl-CoA, the main reaction within the complex, it 
would therefore adapt earlier to accommodate the need for increased oxidation, an idea 
which had been previously proposed for other tissues (Maury et al. 1995). In the case of 
skeletal muscle of PDK2 KO mice, higher El-a protein seems to be a possible 
compensatory strategy to allow for improved PDHa activity by increasing the expression 
of this rate-limiting subunit. This is especially important in these PDK2 KO mice during 
exercise, since they appear to have increased difficulty activating or 'turning on' the 
complex even at low-to-moderate contraction stimuli. 
The protein content of the E2 subunit was slightly, but not significantly higher in 
PDK2 KO mice, similar to what was observed in human skeletal muscle after 8 weeks of 
training (LeBlanc et al. 2004). This suggests that E2 could be undergoing a slower 
adaptive upregulation, following the increase in rate-limiting El-a subunit. However, 
these adaptations to increase PDH activity through the upregulation of the PDH subunit 
do not reflect a generalized increase in muscle oxidative capacity, because COX IV (a 
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subunit of the cytochrome c oxidase enzyme of the electron transport chain) was 
unchanged in the PDK2 KO compared to the WT mice. 
PDKI expression in the PDK2 KOs - mediated by HIF·l? 
The increased expression of PDKI seen in this study has also been observed in 
hypoxic cultured mouse and human cells (Kim et al. 2006, Fukuda et al. 2007). Although 
our PDK2 KO mice are not deprived of oxygen, their expression profile is similar to what 
has been previously observed during hypoxia, and has been linked to hypoxia-inducible 
factor 1 (HIF-I), a transcription factor that appears to be responsible for 'balancing' 
redox in the electron transport chain. In hypoxia, there is a decrease in the amount of O2 
delivered to the ETC and, as a result, there has been an observed increase in PDKl, 
thought to cause a reduction of NADH influx into the ETC, while decreasing COXIV 
activity by shifting expression from. the first COX IV isoform to the second more 
productive COX IV isoform, thereby increaseing complex IV activity (as reviewed by 
Semenza, 2008). While there was not an observed change in COX IV protein in the 
PDK2 KO mice, it is possible that such as shift obscured by the fact that our antibody 
detected both COXIV isoforms. While it is not immediately clear how deleting the 
PDK2 isoform would stimulate the same transcription profile as that seen during hypoxia, 
it warrants further attention. It is possible that by deleting the most abundant isoform and 
by dropping total PDK activity so low, the muscle adapts to decrease the unregulated 
influx of carbohydrate-derived reducing equivalents to the ETC through the transcription 
factor HIF-I. 
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Future Studies 
Future studies are required to fully explore the role of the PDKl isoform, 
specifically during exercise. From this work, it might be suitable to term this isoform the 
"small but mighty" isoform, since relatively little of it seems to be very potent in 
changing PDH regulation due to its sensitivities to allosteric regulators that are changing 
during muscle contraction. It was observed in this study that in the absence ofPDK2, 
PDKl was upregulated in a possible compensatory strategy which potentially resulted in 
decreased PDHa activity during low and moderate intensity stimulation, but a thorough 
understanding of its normal role in the full complement of PDH kinases is yet to be 
understood. 
Previous research on the PDKl isoform has been severely limited primarily due to 
the very small relative concentration of this isoform in mixed muscle, and the complete 
lack of effect any nutritional or training perturbation has had on PDKl protein content. 
PDKl is known to only phosphorylate site 3 which makes it difficult to reactivate PDH. 
Phospho-specific antibodies could be used to fully understand the mechanism of site 3 
phosphorylation on El-a and subsequently understand PDKl as well. The removal of the 
PDK2 isoform generated an increase in PDKl protein leads to the obvious next step of 
PDK2 and PDK4 double KO mice. These double KO mice would allow for more specific 
and singular physiological research to examine the PDKl isoform, by removing the two 
major kinases and observing PDKl in isolation. 
This study focussed primarily on the PDK isoforms and their roles in regulating 
PDH complex activity, however, the PDP isoforms are also a major component of PDH 
complex regulation. Specifically, how does PDPl, an isoform that has been shown to 
increase with exercise training, affect PDHa activity in the PDK2 KO mice at rest or 
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during acute contraction? Further characterization of the PDP isoforms in these PDK2 
KO mice is needed to fully understand the effect of the removal of the PDK2 isoform and 
the subsequent lower PDHa activity. 
Another major and unexpected finding that requires more attention is the potential 
link between the upregulation of PDKI and the transcription factor HIF-l. Further work 
is necessary to examine differences in HIF-l expression in PDK2 KO mice, and how 
these adaptive changes occur over time. It is also important to obtain a more specific 
antibody for COX IV that separates the two COX IV isoforms to determine whether there 
was a shift from COX IV -1 to COX IV -2 as seen during hypoxia. 
To our knowledge, the individual PDH components have not been as extensively 
studied during nutritional and exercise perturbations, and the increase that was seen in 
this study in PDK2 KO mice, might have implications during other situations. More 
information regarding the potentially slower upregulation of the E2 subunit is needed. Is 
there an adaptive upregulation of the E2 subunit with the removal of the PDK2 isoform, 
and why is the increase in E2 so much slower in comparison to the El-a subunit? 
Summary and Perspectives 
There are many aspects of fuel regulation and utilization that remain unknown. 
This study set out to examine the role that the PDK2 isoform played at rest and during 
low and moderate intensity contraction, and also observed that total PDK activity may 
not be as important in determining carbohydrate flux through oxidation during 
contraction. It seems that the overall kinetic and allosteric properties of the collective 
PDK isoform population have a greater influence on carbohydrate flux. This study 
removed the most abundant PDK isoform, thereby revealing the normal inhibitory role of 
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the other two isoforms on the PDH complex. Essentially, under normal circumstances 
PDK2 seems to playa role in 'fine-tuning' the activation of the complex because of its 
acute sensitivity to pyruvate inhibition. It 'dilutes' out the overly inhibitory properties of 
the other two isoforms. However, this study was also the first physiological evidence that 
PDKI is actually a very potent inhibitor of the PDH complex, which raises questions as 
to why it would be present in skeletal muscle at alL However, PDKI is more abundant in 
heart muscle (Bowker-Kinley et al. 1998) and in oxidative skeletal muscle (Peters et aL 
2001) which are both tissues that have an increased reliance on fat. Therefore, PDKI may 
playa role in promoting potent inhibition of the PDH complex, and thereby increasing fat 
oxidation in these tissues. 
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Appendix 
Pyruvate dehydrogenase kinase specialist properties 
(Adapted/rom Bowker-Kinley 1998 and Sudgen 2003) 
PDKI PDK2 PDK3 
Site specific activity for highest activity lowest activity 
phosphorylation site 3 towards site 1 towards site 1 
KmforATP 60±5 10 ± 1 50±5 
(J.lM) 
highest affinity 
Kifor ADP 370±20 120 ± 20 80± 10 
(J.lM) 
sensitivity is similar 
to PDK4 
Ki for DCA 1.0 ± 0.2 0.2 ±0.05 8.0 ± 1.0 
(ruM) 
more sensitive to 
DCA vs PDK4 and 
PDKI 
Effector 120% 130% 110% 
Sensitivity 
NADH 
(% of control) 
NADH + acetyl- 180% 320% 60% 
CoA 
(% of control) highest sensitivity 
Effect of: 
No change in No change No change 
Starvation protein or 
mRNA 
expression 
High Fat Diet No change No change No change 
60 
PDK4 
highest activity 
towards site 2 
65 ±6 
100 ± 15 
0.5 ±0.2 
190% 
highest 
sensitivity 
150% 
Increase in 
protein and 
mRNA 
expression 
Increase in 
protein and 
mRNA 
expression 
Chemically· No change No change No change Increase in 
Induced protein and 
Diabetes mRNA 
expression 
Exercise No change Increase in protein No change No change 
andmRNA 
expression 
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Breakdown of SIGMA medium-199 
Product Name 
Product Number 
TEST 
APPEARANCE 
PH TEST 
OSMOLALITY TEST 
STERILITY BY USP 
ENDOTOXIN ASSAY 
GLUCOSE CONTENT 
CELL CULTURE TEST 
EXPIRATION DATE 
Components 
Inorganic Salts 
CaCh'2H20 
Fe(N03h9H20 
MgS04 (anhyd) 
KCI 
KH2P04 
NaAcetate (anhyd) 
NaHC03 
NaCI 
Na2HP04 (anhyd) 
NaH2P04 (anhyd) 
Amino Acids 
DL-Alanine 
L-Arginine·HCI 
DL-Aspartic Acid 
L-Cysteine·HCI·H20 
L-Cystine.2HCI 
DL-Glutamic Acid 
L-Glutamine 
Glycine 
L-HistidineHCl"H20 
Hydroxy-L-Proline 
D L-Isoleucine 
Medium-199 
M4530 
0.122 
M4350 
[IX] 
g"L-1 
0.265 
0.00072 
0.9767 
0.4 
0.05 
2.2 
6.8 
0.05 
0.07 
0.06 
0.00011 
0.026 
0.1336 
0.1 
0.05 
0.02188 
0.01 
0.04 
62 
SPECIFICATION 
CLEAR SOLUTION 
7.0-7.6 
280-310 mOsm·kg-1 
STERILE 
NMT 1EUIML 
0.9-1.1 g.-l 
PASS 
12 MONTHS 
I 
I; 
.. ~ 
DL-Leucine 
L-LysineoHCI 
D L-Metthionine 
D L-Phenylalanine 
L-Proline 
DL-Serine 
DL-Threonine 
DL-Tryptophan 
L-Tyrosine 2Na"2H20 
DL-Valine 
Vitamins 
Ascorbic AcidoNa 
D-Biotin 
Calciferol 
Choline Chloride 
Folic Acid 
Menadione (sodium bisulfite) 
Myo-Inositol 
Niacinamide 
Nicotinic Acid 
0.0005 
0.12 
0.07 
0.03 
0.05 
0.04 
0.05 
0.06 
0.02 
0.05766 
0.05 
0.000056 
0.00001 
0.0001 
0.00001 
0.000016 
0.00005 
0.000025 
0.000025 
0.00005 p-Amino Benzoic Acid 
D-Pantothenic Acido1/2Ca 
PyridoxalHCI 
PydridoxineHCl 
Retinol Acetate 
Riboflavin 
0.00001 
0.000025 
0.000025 
0.00014 
0.00001 
DL-a-Tocopherol PhosphateNa 
ThiamineHCI 
Other 
Adenine Sulfate 
Adenosine Triphosphateo2Na 
Adenosine MonophosphateNa 
Cholesterol 
Deoxyribose 
Glucose 0.1 
Gluthathione (reduced) 
Guanine.HCl 
HEPES 
Hypoxanthine 
Phenol RedNa 
Tween 80 
Ribose 
Thymine 
0.00001 
0.00001 
0.01 
0.001 
0.000238 
0.0002 
0.0005 
0.00005 
0.0003 
0.0003 
0.0213 
0.02 
0.0005 
0.0003 
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Uracil 
Xanthine.N a 
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